Page 9 - Master File News Today

Without being approved by the WHO or the FDA, Covaxin is unlikely to be accepted as a legitimate vaccine by many countries.

Ocugen, the US partner of Bharat Biotech claimed the company will now be seeking full approval of Covaxin.

Ocugen, the US partner of Bharat Biotech claimed the company will now be seeking full approval of Covaxin.

The FDA has recommended that recommended Ocugen pursue a BLA submission instead of an EUA application for Covaxin.

USFDA last month came out with a revised guideline for covid vaccine approval that said it will no longer grant emergency authorization to new applications. In some countries, people vaccinated with both the doses of Covaxin have been treated as unvaccinated.

Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics license application (BLA) for Covaxin.

Indian students in the US who got themselves vaccinated with Covaxin or Sputnik V have been asked to get themselves re-vaccinated citing lack of WHO approval

TOKYO--(BUSINESS WIRE)--Mitsubishi Engineering-Plastics Corporation (MEP), a world leader in high-performance polyacetal materials, has developed a new polyacetal resin (POM), the Iupital MA Series, that is compliant with medical standards.The MA series is available in a range of standard, high-flow, high-rigidity,...

Ocugen Inc (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, has submitted a “Master ...

Ocugen submits ‘Master File’ to FDA on Covid vaccine Covaxin PTI Hyderabad | Updated on Bharat Biotech’s US partner is targeting 100 million doses per annum beginning 2021 Ocugen, Bharat Biotech’’s American partner for Covid-19 vaccine Covaxin, has submitted a “Master File” to the US Food and Drug Administration prior to seeking an emergency use authorisation in that country. “The company is currently evaluating the clinical and regulatory path for Covaxin in the US, including ...